1. Home
  2. FMST vs CNSY Comparison

FMST vs CNSY Comparison

Compare FMST & CNSY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foremost Lithium Resource & Technology Ltd.

FMST

Foremost Lithium Resource & Technology Ltd.

HOLD

Current Price

$0.96

Market Cap

22.3M

ML Signal

HOLD

Logo Cerenome Inc. Common Stock

CNSY

Cerenome Inc. Common Stock

N/A

Current Price

$2.76

Market Cap

20.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FMST
CNSY
Founded
2005
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.3M
20.6M
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
FMST
CNSY
Price
$0.96
$2.76
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
78.3K
65.6K
Earning Date
05-21-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
87.61
EPS
N/A
N/A
Revenue
N/A
$5,213,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.99
$2.62
52 Week High
$4.57
$4.03

Technical Indicators

Market Signals
Indicator
FMST
CNSY
Relative Strength Index (RSI) 31.78 32.12
Support Level N/A $2.62
Resistance Level $1.94 $3.28
Average True Range (ATR) 0.08 0.21
MACD -0.01 -0.02
Stochastic Oscillator 5.63 37.56

Price Performance

Historical Comparison
FMST
CNSY

About FMST Foremost Lithium Resource & Technology Ltd.

Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.

About CNSY Cerenome Inc. Common Stock

Cerenome Inc is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company's CNSide Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its therapeutic platform, REYOBIQ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

Share on Social Networks: